Apoptosis, bcl-2 protein, and Fas antigen in thymic epithelial tumors

Modern Pathology

Volumn 10, Issue 10, 1997, Pages 983-991

  Tateyama, Hisashi ^a   Eimoto, Tadaaki ^a   Tada, Toyohiro ^a   Inagaki, Hiroshi ^a   Hattori, Hideo ^a   Takino, Hisashi ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Apoptosis; bcl 2; Fas; Thymic carcinoma; Thymoma; Thymus

Indexed keywords

FAS ANTIGEN; PROTEIN BCL 2;

ANTIGEN DETECTION; APOPTOSIS; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; THYMUS CANCER; TUMOR BIOPSY;

ADULT; AGED; ANTIGENS, CD95; APOPTOSIS; CARCINOMA; CELL COUNT; DNA FRAGMENTATION; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; THYMOMA; THYMUS NEOPLASMS;

EID: 0030786725     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Rosai J, Levine GD. Tumors of the thymus. In: Firminger HI, editor. Atlas of tumor pathology. 2nd series. Fascicle 13. Washington, DC: Armed Forces Institute of Pathology; 1976. p. 34-7.
2. Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concept. Hum Pathol 1987;9:495-515.
3. Suster S, Rosai J. Thymic carcinoma: a clinicopathological study of 60 cases. Cancer 1991;67:1025-32.
4. Marino M, Müller-Hermelink HK. Thymoma and thymic carcinoma. Relation of thymoma epithelial cells to the cortical and medullary differentiation of thymus. Virchows Archiv A Pathol Anat Histopathol 1985;407:119-49.
5. Kirchner T, Müller-Hermelink HK. New approaches to the diagnosis of thymic epithelial tumors. Prog Surg Pathol 1989; 10:167-89.
6. Kirchner T, Schalke B, Buchwald J, Ritter M, Marx A, Müller-Hermelink HK. Well-differentiated thymic carcinoma: an organotypical low-grade carcinoma with relationship to cortical thymoma. Am J Surg Pathol 1992;16:1153-69.
7. Quintanilla-Martinez L, Wilkins EW Jr, Ferry JA, Harris NL. Thymoma-morphologic subclassification correlates with invasiveness and immunohistologic features: a study of 122 cases. Hum Pathol 1993;24:958-69.
8. Quintanilla-Martinez L, Wilkins EW Jr, Choi N, Efird J, Hug E, Harris NL. Thymoma: histologic subclassification is an independent prognostic factor. Cancer 1994;74:606-17.
9. Kuo T-T, Lo S-K. Thymoma: a study of the pathologic classification of 71 cases with evaluation of the Muller-Hermelink system. Hum Pathol 1993;24:766-71.
10. Kornstein MJ, Curran WJ Jr, Turrisi AT III, Brooks JJ. Cortical versus medullary thymomas: a useful morphologic distinction? Hum Pathol 1988;19:1335-9.
11. Shimosato Y. Controversies surrounding the subclassification of thymoma. Cancer 1994;74:542-4.
12. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
13. Afanas'ev VN, Korol BA, Mantsygin YA, Nelipovich PA, Pechatnikov VA, Umansky SR. Flow cytometry and biochemical analysis of DNA degradation characteristic of two types of cell death. FEBS Lett 1986;194:347-50.
14. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
15. Majno G, Joris I. Apoptosis, oncosis, and necrosis: an overview of cell death. Am J Pathol 1995;146:3-15.
16. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-6.
17. Arends MJ, Morris RG, Wyllie AH. Apoptosis: the role of the endonuclease. Am J Pathol 1990;136:593-608.
18. Wyllie AH. Apoptosis: cell death under homeostatic control. Arch Toxicol 1987;11:3-10.
19. Hockenbery DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
20. Korsmeyer SJ. bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86.
21. Stewart BW. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 1994;86:1286-96.
22. Kastan MB, Canman CE, Leonard CJ. p53, cell cycle control, and apoptosis: implications for cancer. Cancer Metastasis Rev 1995;14:3-15.
23. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-56.
24. Trauth BC, Klas C, Peters AMJ, Matzku S, Moller P, Falk W, et al. Monoclonal antibody mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
25. Watanabe-Fukunaga R, Brannan C, Itoh N, Yonehara S, Copeland NG, Jenkins NA, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992;148:1274-9.
26. Oehm A, Behrmann I, Falk W, Pawlita M, Mailer G, Klas C, et al. Purification and molecular cloning of the APO-1 antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: sequence identity with the Fas antigen. J Biol Chem 1992;267:10709-15.
27. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-29.
28. Owen-Schaub LB, Radinsky R, Kruzel E, Berra K, Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 1994;54:1580-6.
29. Vollmers HP, Dammrich J, Hensel F, Ribbert H, Meyer-Bahlburg A, Ufken-Gaul T, et al. Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Cancer 1997;79:433-40.
30. Brocheriou I, Carnot F, Briere J. Immunohistochemical detection of bcl-2 protein in thymoma. Histopathology 1995; 27:251-5.
31. Chen F-F, Yan J-J, Jin Y-T, Su I-J. Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness. Hum Pathol 1996;27:1089-92.
32. Chen F-F, Yan J-J, Chang K-C, Lai W-W, Chen RM-Y, Jin Y-T. Immunohistochemical localization of mcl-1 and bcl-2 proteins in thymic epithelial tumours. Histopathology 1996;29: 541-7.
33. Tateyama H, Eimoto T, Tada T, Mizuno T, Inagaki H, Hata A, et al. p53 protein expression and p53 gene mutation in thymic epithelial tumors: an immunohistochemical and DNA sequencing study. Am J Clin Pathol 1995;104:375-81.
34. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-92.
35. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
36. Garcia RL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissue: comparison with flow cytometric analysis. Am J Pathol 1989;134:733-9.
37. Gown AM, de Wever N, Battifora H. Microwave-based antigenic unmasking: a revolutionary new technique for routine immunohistochemistry. Appl Immunohistochem 1993;1:256-66.
38. Suster S, Moran CA. Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma: a clinicopathologic study of 22 cases. Am J Surg Pathol 1996;20:1469-80.
39. Lipponen PK, Aaltomaa S, Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumours. Histopathology 1996;28:135-40.
40. O'Neill AJ, Staunton MJ, Gaffney EF. Apoptosis occurs independently of bcl-2 and p53 overexpression in non-small cell lung carcinoma. Histopathology 1996;29:45-50.
41. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996;105: 341-9.
42. Todd D, Yang G, Brown RW, Cao J, D'Agati V, Thompson TS, et al. Apoptosis in renal cell carcinoma: detection by in situ end-labeling of fragmented DNA and correlation with other prognostic factors. Hum Pathol 1996;27:1012-7.
43. Soini Y, Paakko P. Extent of apoptosis in relation to p53 and bcl-2 expression in germ cell tumors. Hum Pathol 1996;27: 1221-6.
44. Onodera J, Nakamura S, Nagano I, Tobita M, Yoshioka M, Takeda A, et al. Upregulation of bcl-2 protein in the myasthenic thymus. Annu Neurol 1996;39:521-8.
45. LeBrun DP, Warnke RA, Cleary ML. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 1993;142:743-53.
46. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A 1986;83: 5214-8.
47. Pezzella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990;137:225-32.
48. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. bcl2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 1991;88:6961-5.
49. Lu Q-L, Poulsom R, Wong L, Hanby AM. bcl-2 expression in adult and embryonic nonhaematopoietic tissues. J Pathol 1993;169:431-7.
50. Bronner MP, Culin C, Reed JC, Furth EE. The bcl-2 protooncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 1995;146:20-6.
51. Rosai J. Ackerman's surgical pathology. 8th ed. St. Louis, MO: Mosby; 1996. p. 442-57.
52. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608.
53. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am J Pathol 1994;145:1323-36.
54. Panse J, Hipp ML, Bauer G. Fibroblasts transformed by chemical carcinogens are sensitive to intercellular induction of apoptosis: implications for the control of oncogenesis. Carcinogenesis 1997;18:259-64.
55. Koji T, Kobayashi N, Nakanishi Y, Yoshii A, Hashimoto S, Shibata Y, et al. Immunohistochemical localization of Fas antigen in paraffin sections with rabbit antibodies against human synthetic Fas peptides. Acta Histochem Cytochem 1994;27:459-63.
56. Mallett S, Barclay AN. A new superfamily of cell surface proteins related to the nerve growth factor receptor. Immunol Today 1991;12:220-3.
57. Erikstein BK, Smeland EB, Blomhoff HK, Funderud S, Prydz K, Lessauer W, et al. Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes. Eur J Immunol 1991;21:1033-7.
58. Heller RA, Song K, Fan N, Chang DJ. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell 1992;70:47-56.
59. Tateyama H, Mizuno T, Tada T, Eimoto T, Hashimoto T, Masaoka A. Thymic epithelial tumours: evaluation of malignant grade by quantification of proliferating cell nuclear antigen and nucleolar organizer regions. Virchows Archiv A Pathol Anat Histopathol 1993;422:265-9.